TherapeuticsMD Inc.
TXMD | NASDAQ
$2.16
+$0.06 (+2.86%)
Sep 22, 2026, 4:00 PM ET · Market open
Company Profile
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Key Executives
| Name | Position |
|---|---|
| Marlan D. Walker | Chief Executive Officer |
| Joseph A. Ziegler | Principal Financial & Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 05, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| Apr 06, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Apr 01, 2026 | 10-K/A | [Amend] Annual Report |
| Apr 01, 2026 | NT 10-K | Filing |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 10-K | Annual Report |
TherapeuticsMD Inc.
| Country | United States |
| IPO Date | May 8, 2007 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Marlan D. Walker |
Contact Details
951 Yamato Road Boca Raton,
Florida 33431 United States
Stock Details
| Ticker Symbol | TXMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000025743 |
| CUSIP Number | 88338N206 |
| ISIN Number | US88338N2062 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove TXMD